Page de couverture de Pharmanomics

Pharmanomics

How Big Pharma Destroys Global Health

Aperçu

Essayer pour 0,00 $
Choisissez 1 livre audio par mois dans notre incomparable catalogue.
Écoutez à volonté des milliers de livres audio, de livres originaux et de balados.
L'abonnement Premium Plus se renouvelle automatiquement au tarif de 14,95 $/mois + taxes applicables après 30 jours. Annulation possible à tout moment.

Pharmanomics

Auteur(s): Nick Dearden
Narrateur(s): Gareth Richards
Essayer pour 0,00 $

14,95$ par mois après 30 jours. Annulable en tout temps.

Acheter pour 22,26 $

Acheter pour 22,26 $

Confirmer l'achat
Payer avec la carte finissant par
En confirmant votre achat, vous acceptez les conditions d'utilisation d'Audible et la déclaration de confidentialité d'Amazon. Des taxes peuvent s'appliquer.
Annuler

À propos de cet audio

In Pharmanomics, investigative journalist Nick Dearden digs down into the way we produce our medicines and finds that Big Pharma is failing us, with catastrophic consequences.

Big Pharma is more interested in profit than health. This was made clear as governments rushed to produce vaccines during the Covid pandemic. Behind the much-trumpeted scientific breakthroughs, major companies found new ways of gouging billions from governments in the West while abandoning the Global South. But this is only the latest episode in a long history of financializing medicine—from Purdue's rapacious marketing of highly addictive OxyContin through Martin Shkreli's hiking the price of a lifesaving drug to the 4.5 million South Africans needlessly deprived of HIV/AIDS medication.

Since the 1990s, Big Pharma has gone out of its way to protect its property through the patent system. As a result, the business has focused not on researching new medicines but on building monopolies. This system has helped restructure our economy away from invention and production in order to benefit financial markets. It has fundamentally reshaped the relationship between richer and poorer countries, as the access to new medicines and the permission to manufacture them is ruthlessly policed. In response, Dearden offers a pathway to a fairer, safer system for all.

©2023 Nick Dearden (P)2023 Tantor
Affaires et carrières Médecine et secteur de la santé Politiques publiques Études futures Entreprise Pharmacologie
activate_Holiday_promo_in_buybox_DT_T2

Ce que les auditeurs disent de Pharmanomics

Moyenne des évaluations de clients

Évaluations – Cliquez sur les onglets pour changer la source des évaluations.